EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Statera BioPharma's Enterprise Value is €0.00 Mil.
Statera BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2022 was €-10.99 Mil. Therefore, Statera BioPharma's EV-to-FCF for today is 0.00.
The historical rank and industry rank for Statera BioPharma's EV-to-FCF or its related term are showing as below:
STU:7CB'
s EV-to-FCF Range Over the Past 10 Years
Min: -45.31 Med: -36.36 Max: -24.59
Current: -0.57
During the past 3 years, the highest EV-to-FCF of Statera BioPharma was -24.59. The lowest was -45.31. And the median was -36.36.
STU:7CB's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 5.935
vs STU:7CB: -0.57
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Statera BioPharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Statera BioPharma's EV-to-FCF
For the Biotechnology subindustry, Statera BioPharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Statera BioPharma's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Statera BioPharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Statera BioPharma's EV-to-FCF falls into.
Statera BioPharma's current Enterprise Value is €0.00 Mil.
Statera BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Statera BioPharma (STU:7CB) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Statera BioPharma's PE Ratio for today is calculated as:
Statera BioPharma's share price for today is €0.00.
Statera BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Statera BioPharma EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Statera BioPharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STU:7CB has been successfully added to your 